Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Stakeholder Opinions: Cancer Cachexia - Higher profile needed to unlock market potential of neglected syndrome

Published by: Datamonitor

Published: Jan. 30, 2009


Table of Contents


Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Abstract

Introduction

Cancer cachexia is a muscle and fat wasting syndrome that affects the majority of incurable cancer patients and adversely impacts treatment outcomes, survival and quality of life. Current treatment options for cancer cachexia are limited. The lack of a universal objective definition and the low profile of the condition among oncologists have restricted advances in treatment.

Scope
  • Cancer cachexia overview, including definition of the condition, pathophysiology and patient population estimates in the seven major markets
  • Treatment of cancer cachexia, including discussion of drug therapies currently available and unmet needs
  • Examination of cancer cachexia pipeline activity including profiles of late-phase pipeline drugs and clinical trial design discussion
  • Stakeholder opinions based on qualitative interviews with opinion leaders in the field of cancer cachexia
Highlights

The lack of effective drug therapy is the biggest unmet need in cancer cachexia. Megestrol acetate is used off-label but does not increase lean body mass. Corticosteroids are also used off-label, but their side effect profile restricts use to a short-term basis. A multimodal approach to therapy may be the best way of improving treatment outcomes.

Several different types of clinician are involved in the management of cancer cachexia, but oncologists have the greatest influence. Drug companies should raise awareness of cachexia among oncologists to improve treatment and build a market. This may also help to promote a more universal multidisciplinary team approach to cancer cachexia care.

Developers of cancer cachexia drugs face several large hurdles. The lack of a universal, objective definition of cancer cachexia means that there is uncertainty over which patients to recruit for clinical trials. Furthermore, controversy surrounds clinical trial endpointsit is unclear which endpoints should be use and how to measure a response.

Reasons to Purchase
  • Assess the size of the cancer cachexia population (both overall and for specific tumor types) in the seven major markets
  • Understand unmet needs in cancer cachexia and the challenges facing developers of drugs for cancer cachexia
  • Identify products in clinical development for cancer cachexia. Consider, assess and react to opportunities and risks influencing their potential


Please Note: This product is delivered as a zip file

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/15/2012 - 32